Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 106

1.

Heparanase procoagulant activity is elevated in women using oral contraceptives.

Matan M, Axelman E, Brenner B, Nadir Y.

Hum Reprod. 2013 Sep;28(9):2372-80. doi: 10.1093/humrep/det257. Epub 2013 Jun 25.

PMID:
23800622
[PubMed - indexed for MEDLINE]
Free Article
2.

An assay to evaluate heparanase procoagulant activity.

Nadir Y, Kenig Y, Drugan A, Shafat I, Brenner B.

Thromb Res. 2011 Oct;128(4):e3-8. doi: 10.1016/j.thromres.2011.03.008. Epub 2011 Apr 8.

PMID:
21481923
[PubMed - indexed for MEDLINE]
3.

Increased heparanase level and procoagulant activity in orthopedic surgery patients receiving prophylactic dose of enoxaparin.

Peled E, Rovitsky A, Axelman E, Norman D, Brenner B, Nadir Y.

Thromb Res. 2012 Jul;130(1):129-34. doi: 10.1016/j.thromres.2011.09.021. Epub 2011 Dec 10.

PMID:
22154361
[PubMed - indexed for MEDLINE]
4.

[Cardiovascular risks of oral contraceptives: dose-response relationship].

Kelleher CC.

Contracept Fertil Sex (Paris). 1991 Apr;19(4):285-8. French.

PMID:
12343220
[PubMed - indexed for MEDLINE]
5.

Studies on oral contraceptive-induced changes in blood coagulation and fibrinolysis and the estrogen effect on endothelial cells.

Quehenberger P, Kapiotis S, Pärtan C, Schneider B, Wenzel R, Gaiger A, Speiser W.

Ann Hematol. 1993 Jul;67(1):33-6.

PMID:
8392873
[PubMed - indexed for MEDLINE]
6.

Heparanase procoagulant activity.

Nadir Y, Brenner B.

Thromb Res. 2012 Apr;129 Suppl 1:S76-9. doi: 10.1016/S0049-3848(12)70021-X.

PMID:
22682139
[PubMed - indexed for MEDLINE]
7.

Population-based study of risk of venous thromboembolism associated with various oral contraceptives.

Farmer RD, Lawrenson RA, Thompson CR, Kennedy JG, Hambleton IR.

Lancet. 1997 Jan 11;349(9045):83-8.

PMID:
8996419
[PubMed - indexed for MEDLINE]
8.

Disruption of 3D MCF-12A breast cell cultures by estrogens--an in vitro model for ER-mediated changes indicative of hormonal carcinogenesis.

Marchese S, Silva E.

PLoS One. 2012;7(10):e45767. doi: 10.1371/journal.pone.0045767. Epub 2012 Oct 2.

PMID:
23056216
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Changes in haemostatic variables induced by oral contraceptives containing 50 micrograms or 30 micrograms oestrogen: absence of dose-dependent effect on PAI-1 activity.

Scarabin PY, Plu-Bureau G, Zitoun D, Bara L, Guize L, Samama MM.

Thromb Haemost. 1995 Sep;74(3):928-32.

PMID:
8571323
[PubMed - indexed for MEDLINE]
10.

Molecular mechanisms of estrogen action: selective ligands and receptor pharmacology.

Katzenellenbogen BS, Choi I, Delage-Mourroux R, Ediger TR, Martini PG, Montano M, Sun J, Weis K, Katzenellenbogen JA.

J Steroid Biochem Mol Biol. 2000 Nov 30;74(5):279-85. Review.

PMID:
11162936
[PubMed - indexed for MEDLINE]
11.

Changes in coagulation and anticoagulation in women taking low-dose triphasic oral contraceptives: a controlled comparative 12-month clinical trial.

Notelovitz M, Kitchens CS, Khan FY.

Am J Obstet Gynecol. 1992 Nov;167(5):1255-61.

PMID:
1442974
[PubMed - indexed for MEDLINE]
12.
13.

Estrogens, selective estrogen receptor modulators, and a selective estrogen receptor down-regulator inhibit endothelial production of tissue factor pathway inhibitor 1.

Dahm AE, Iversen N, Birkenes B, Ree AH, Sandset PM.

BMC Cardiovasc Disord. 2006 Oct 9;6:40.

PMID:
17029634
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Heparanase enhances the generation of activated factor X in the presence of tissue factor and activated factor VII.

Nadir Y, Brenner B, Fux L, Shafat I, Attias J, Vlodavsky I.

Haematologica. 2010 Nov;95(11):1927-34. doi: 10.3324/haematol.2010.023713. Epub 2010 Jul 15.

PMID:
20634491
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Increased levels of activated factor VII and decreased plasma protein S activity and circulating thrombomodulin during use of oral contraceptives.

Quehenberger P, Loner U, Kapiotis S, Handler S, Schneider B, Huber J, Speiser W.

Thromb Haemost. 1996 Nov;76(5):729-34.

PMID:
8950781
[PubMed - indexed for MEDLINE]
16.

A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways.

Tans G, Curvers J, Middeldorp S, Thomassen MC, Meijers JC, Prins MH, Bouma BN, Büller HR, Rosing J.

Thromb Haemost. 2000 Jul;84(1):15-21.

PMID:
10928463
[PubMed - indexed for MEDLINE]
17.

Monocyte tissue factor expression is enhanced in women who smoke and use oral contraceptives.

Hölschermann H, Terhalle HM, Zakel U, Maus U, Parviz B, Tillmanns H, Haberbosch W.

Thromb Haemost. 1999 Dec;82(6):1614-20.

PMID:
10613644
[PubMed - indexed for MEDLINE]
18.

Estrogen-dependent rapid activation of protein kinase C in estrogen receptor-positive MCF-7 breast cancer cells and estrogen receptor-negative HCC38 cells is membrane-mediated and inhibited by tamoxifen.

Boyan BD, Sylvia VL, Frambach T, Lohmann CH, Dietl J, Dean DD, Schwartz Z.

Endocrinology. 2003 May;144(5):1812-24.

PMID:
12697687
[PubMed - indexed for MEDLINE]
19.

Estrogen receptor-dependent and estrogen receptor-independent pathways for tamoxifen and 4-hydroxytamoxifen-induced programmed cell death.

Obrero M, Yu DV, Shapiro DJ.

J Biol Chem. 2002 Nov 22;277(47):45695-703. Epub 2002 Sep 19.

PMID:
12244117
[PubMed - indexed for MEDLINE]
Free Article
20.

Tamoxifen and ICI 182,780 negatively influenced cardiac cell growth via an estrogen receptor-independent mechanism.

Mercier I, Mader S, Calderone A.

Cardiovasc Res. 2003 Oct 1;59(4):883-92.

PMID:
14553828
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk